Quick facts
Research Use Only
Early Human Trials
What is Melanotan II?
Melanotan II is an investigational compound designed to mimic a natural hormone that stimulates the production of melanin, the pigment that darkens skin. Originally developed to study skin cancer prevention, researchers found it also has effects on the central nervous system. It is currently studied for its potential to promote skin pigmentation with less sun exposure and to support sexual arousal.
Common Uses
In clinical research, Melanotan II was associated with increased melanin production, leading to skin darkening with minimal UV exposure.
Research suggests Melanotan II acts on the central nervous system to support sexual arousal and erectile function in men.
Early clinical studies noted that Melanotan II was associated with mild appetite suppression in some participants.
Melanotan II was originally studied for its potential to provide a protective tan to reduce the risk of UV-induced skin damage.
Studies & Clinical Research
Melanotan II is an investigational compound that mimics a natural hormone to stimulate melanin production. In research, Melanotan II was associated with increased skin pigmentation and effects on sexual arousal.
Melanotan II is an investigational compound and is not FDA-approved. It has been associated with side effects such as nausea, facial flushing, increased blood pressure, and changes in moles or freckles. A licensed provider should be consulted before use.
In clinical studies, changes in skin pigmentation with Melanotan II were typically observed within a few weeks of consistent use, often requiring some UV exposure. Effects on arousal were noted more rapidly.
Yes. Melanotan II is not FDA-approved and is an investigational compound. A licensed healthcare provider should review your health history before you consider Melanotan II.
Have a question you don’t see answered?
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.